Business
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
OSAKA, Japan & CAMBRIDGE, Mass., October 22, 2025--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for the development, manufacturing and commercialization of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China.* IBI363 is being evaluated in non-small cell lung and colorectal cancers and has shown potential efficacy in additional solid tumor types. IBI343 is being
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":266,"url":"https://media.zenfs.com/en/business-wire.com/b107ae0b0a1de9deea4355b1179aa5be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GZopu2vBbfHW50FPjqOd3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b107ae0b0a1de9deea4355b1179aa5be","width":480,"height":266}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage Program","length":196,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Takeda to Lead IBI363 Global Co-Development and U.S. Co-Commercialization and Will Have Exclusive Commercialization Rights Outside the U.S. and Greater China; IBI363 is a Late-Stage Bispecific Antibody Fusion Protein Being Evaluated in Non-Small Cell Lung and Colorectal Cancers, with Potential in Additional Solid Tumor Types","length":326,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Takeda to Receive Exclusive Rights for IBI343 Outside of Greater China; IBI343 is a Late-Stage Antibody-Drug Conjugate Being Evaluated in Gastric and Pancreatic Cancers","length":168,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Takeda Intends to Establish Manufacturing for These Investigational Medicines in the U.S.","length":89,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":779,"olType":false},{"type":"text","content":"OSAKA, Japan & CAMBRIDGE, Mass., October 22, 2025--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for the development, manufacturing and commercialization of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China.* IBI363 is being evaluated in non-small cell lung and colorectal cancers and has shown potential efficacy in additional solid tumor types. IBI343 is being evaluated in gastric and pancreatic cancers. Takeda will also receive an exclusive option to license global rights outside of Greater China for IBI3001, an earl...